The nightmare on the public markets is not confined to the bigger groups.
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Shareholders are rewarding the kinds of companies they punished a year ago.
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
It takes more than a pandemic to stop medical device companies merging.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.